<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35997623</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1465-2099</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of general virology</Title><ISOAbbreviation>J Gen Virol</ISOAbbreviation></Journal><ArticleTitle>Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">001771</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1099/jgv.0.001771</ELocationID><Abstract><AbstractText>Enterovirus A71 (EVA71) infection can result in paralysis and may be fatal. In common with other picornaviruses, empty capsids are produced alongside infectious virions during the viral lifecycle. These empty capsids are antigenically indistinguishable from infectious virus, but at moderate temperatures they are converted to an expanded conformation. In the closely related poliovirus, native and expanded antigenic forms of particle have different long-term protective efficacies when used as vaccines. The native form provides long-lived protective immunity, while expanded capsids fail to generate immunological protection. Whether this is true for EVA71 remains to be determined. Here, we selected an antigenically stable EVA71 virus population using successive rounds of heating and passage and characterized the antigenic conversion of both virions and empty capsids. The mutations identified within the heated passaged virus were dispersed across the capsid, including at key sites associated with particle expansion. The data presented here indicate that the mutant sequence may be a useful resource to address the importance of antigenic conformation in EVA71 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kingston</LastName><ForeName>Natalie J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shegdar</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snowden</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groppelli</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Present address: Institute for Infection and Immunity, St George's University of London, Tooting, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macadam</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlands</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonehouse</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>102174/B/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>204825/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI169457</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/P022626/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Gen Virol</MedlineTA><NlmUniqueID>0077340</NlmUniqueID><ISSNLinking>0022-1317</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EVA71</Keyword><Keyword MajorTopicYN="N">empty capsids</Keyword><Keyword MajorTopicYN="N">infantile paralysis</Keyword><Keyword MajorTopicYN="N">stabilization</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>23</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35997623</ArticleId><ArticleId IdType="pmc">PMC10019091</ArticleId><ArticleId IdType="doi">10.1099/jgv.0.001771</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ong KC, Wong KT. Understanding enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol. 2015;25:614&#x2013;624. doi: 10.1111/bpa.12279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12279</ArticleId><ArticleId IdType="pmc">PMC8029433</ArticleId><ArticleId IdType="pubmed">26276025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia RK, Gill CM, Baca C, McMenamin C, Kannappan A, et al. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol. 2021;358:577639. doi: 10.1016/j.jneuroim.2021.577639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577639</ArticleId><ArticleId IdType="pubmed">34214953</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubart M, Gitiaux C, Roux CJ, Levy R, Schuffenecker I, et al. Severe acute flaccid myelitis associated with enterovirus in children: two phenotypes for two evolution profiles? Front Neurol. 2020;11:343. doi: 10.3389/fneur.2020.00343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00343</ArticleId><ArticleId IdType="pmc">PMC7198806</ArticleId><ArticleId IdType="pubmed">32411086</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341:936&#x2013;942. doi: 10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Chow VTK, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Phoon MC, Ramachandran NP, Chow VTK, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335&#x2013;2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281&#x2013;3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the asia-pacific region. J Biomed Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13:e1001958. doi: 10.1371/journal.pmed.1001958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001958</ArticleId><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Enterovirus 71. 2022. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/enterovirus-71</Citation></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5:e75. doi: 10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z, Huang Y, Bloom MS, Zhang Z, Yang Z, et al. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. Hum Vaccin Immunother. 2021;17:217&#x2013;223. doi: 10.1080/21645515.2020.1763076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1763076</ArticleId><ArticleId IdType="pmc">PMC7872061</ArticleId><ArticleId IdType="pubmed">32530733</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Liu F, Qi H, Tu W, Ward MP, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study. Lancet Reg Health West Pac. 2022;20:100370. doi: 10.1016/j.lanwpc.2021.100370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol. 1995;142:109&#x2013;140. doi: 10.1093/oxfordjournals.aje.a117611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a117611</ArticleId><ArticleId IdType="pubmed">7598112</ArticleId></ArticleIdList></Reference><Reference><Citation>Offit PA. The Cutter incident, 50 years later. N Engl J Med. 2005;352:1411&#x2013;1412. doi: 10.1056/NEJMp048180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp048180</ArticleId><ArticleId IdType="pubmed">15814877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bull World Health Organ. 2004;82:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585887</ArticleId><ArticleId IdType="pubmed">15106302</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulders MN, Reimerink JH, Koopmans MP, van Loon AM, van der Avoort HG. Genetic analysis of wild-type poliovirus importation into The Netherlands (1979-1995) J Infect Dis. 1997;176:617&#x2013;624. doi: 10.1086/514081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/514081</ArticleId><ArticleId IdType="pubmed">9291306</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 &amp; 2003. Indian J Med Res. 2003;118:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">14870793</ArticleId></ArticleIdList></Reference><Reference><Citation>Duizer E, Rutjes S, de Roda Husman AM, Schijven J. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. Euro Surveill. 2016;21:30169. doi: 10.2807/1560-7917.ES.2016.21.11.30169.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.11.30169</ArticleId><ArticleId IdType="pubmed">27020766</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmons B, Lim PY, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine. 2018;36:6623&#x2013;6630. doi: 10.1016/j.vaccine.2018.09.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.062</ArticleId><ArticleId IdType="pubmed">30293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xiao X, Zhao M, Liu W, Pang L, et al. EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge. BMC Res Notes. 2016;9:42. doi: 10.1186/s13104-015-1780-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-015-1780-x</ArticleId><ArticleId IdType="pmc">PMC4724958</ArticleId><ArticleId IdType="pubmed">26809443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, He YL, Li HY, Chen R. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/Coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J Virol. 2015;89:6196&#x2013;6208. doi: 10.1128/JVI.00422-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, Zhu H, Zhou J, Yang C, Feng J, et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol. 2014;88:6444&#x2013;6452. doi: 10.1128/JVI.00200-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci. 1994;3:1651&#x2013;1669. doi: 10.1002/pro.5560031005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031005</ArticleId><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ST, Hogle JM, Filman DJ. Ab initio phasing of high-symmetry macromolecular complexes: successful phasing of authentic poliovirus data to 3.0 A resolution. J Mol Biol. 2001;307:499&#x2013;512. doi: 10.1006/jmbi.2001.4485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2001.4485</ArticleId><ArticleId IdType="pubmed">11254378</ArticleId></ArticleIdList></Reference><Reference><Citation>Butan C, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol. 2014;88:1758&#x2013;1770. doi: 10.1128/JVI.01949-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01949-13</ArticleId><ArticleId IdType="pmc">PMC3911577</ArticleId><ArticleId IdType="pubmed">24257617</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PNM, Filman DJ, Karunatilaka KS, Hesketh EL, Groppelli E, et al. Cryo-EM structures reveal two distinct conformational states in a picornavirus cell entry intermediate. PLoS Pathog. 2020;16:e1008920. doi: 10.1371/journal.ppat.1008920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008920</ArticleId><ArticleId IdType="pmc">PMC7549760</ArticleId><ArticleId IdType="pubmed">32997730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Ding J, Han J-F, Zhang Y, Wu X-Y, et al. Human enterovirus 71 uncoating captured at atomic resolution. J Virol. 2014;88:3114&#x2013;3126. doi: 10.1128/JVI.03029-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03029-13</ArticleId><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston NJ, Grehan K, Snowden JS, Shegdar M, Macadam AJ, et al. Development of an ELISA for the detection of the native conformation of enterovirus A71. mSphere. 2022;7:e0008822. doi: 10.1128/msphere.00088-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00088-22</ArticleId><ArticleId IdType="pmc">PMC9241546</ArticleId><ArticleId IdType="pubmed">35642505</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyemi OO, Nicol C, Stonehouse NJ, Rowlands DJ. Increasing type 1 poliovirus capsid stability by thermal selection. J Virol. 2017;91:e01586-16. doi: 10.1128/JVI.01586-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01586-16</ArticleId><ArticleId IdType="pmc">PMC5286869</ArticleId><ArticleId IdType="pubmed">27928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog. 2017;13:e1006117. doi: 10.1371/journal.ppat.1006117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006117</ArticleId><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints12. Am J Hyg. 1938;27:493&#x2013;497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajito S, Iwase H, Takata S, Hirai M. Sugar-mediated stabilization of protein against chemical or thermal denaturation. J Phys Chem B. 2018;122:8685&#x2013;8697. doi: 10.1021/acs.jpcb.8b06572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.8b06572</ArticleId><ArticleId IdType="pubmed">30148630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuente JO, Lee H, Yoder JD, Shingler KL, Carnegie MS, et al. Structures of the procapsid and mature virion of enterovirus 71 strain 1095. J Virol. 2013;87:7637&#x2013;7645. doi: 10.1128/JVI.03519-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03519-12</ArticleId><ArticleId IdType="pmc">PMC3700288</ArticleId><ArticleId IdType="pubmed">23637404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wang Y, He W, Sun Y, Guo Y, et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem. 2020;63:1233&#x2013;1244. doi: 10.1021/acs.jmedchem.9b01414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01414</ArticleId><ArticleId IdType="pubmed">31939669</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, et al. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110:5463&#x2013;5467. doi: 10.1073/pnas.1222379110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222379110</ArticleId><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Lee LY, Roivainen M, Filman DJ, Hogle JM, et al. Structure of the Fab-labeled &#x201c;breathing&#x201d; state of native poliovirus. J Virol. 2012;86:5959&#x2013;5962. doi: 10.1128/JVI.05990-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05990-11</ArticleId><ArticleId IdType="pmc">PMC3347258</ArticleId><ArticleId IdType="pubmed">22398295</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyemi OO, Sherry L, Ward JC, Pierce DM, Herod MR, et al. Involvement of a Nonstructural Protein in Poliovirus Capsid Assembly. J Virol. 2019;93:e01447-18. doi: 10.1128/JVI.01447-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01447-18</ArticleId><ArticleId IdType="pmc">PMC6384072</ArticleId><ArticleId IdType="pubmed">30541849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, He F, Meng T, et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012;9:55. doi: 10.1186/1743-422X-9-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-55</ArticleId><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>